Literature DB >> 24114414

Sensitivity to antibiotics of Clostridium difficile toxigenic nosocomial strains.

Vladimir Beran1, Dittmar Chmelar, Jana Vobejdova, Adela Konigova, Jakub Nemec, Josef Tvrdik.   

Abstract

Clostridium difficile is the etiological agent of diarrhoea and colitis, especially in elderly patients. The incidence of these diseases has increased during the last 10 years. Emergence of so-called hypervirulent strains is considered as one of the main factors responsible for the more severe disease and changed profile of sensitivity to antimicrobial agents. The aim of this work was to determine the sensitivity profile of toxigenic strains of C. difficile in the Czech Republic in 2011-2012 to selected antibiotics. The antibiotics clindamycin, metronidazole, vancomycin and amoxicillin with clavulanic acid were used for this purpose. Isolates cultured on Brazier's C. difficile selective agar were analysed for the presence of toxin genes using Xpert detection system. Xpert analysis revealed that 33 strains carried the genes for toxins tcdB, cdt and tcdCΔ117, thus showing characteristics typical for the hypervirulent ribotype 027/PFGE type NAP1/REA type B1. The remaining 29 strains carried only the gene for toxin B (tcdB) and not cdt and tcdCΔ117. Our results indicate the higher susceptibility of C. difficile hypertoxigenic strains to three out of four tested antibiotics (except vancomycin) than it is for the other toxigenic strains. We found that only 10.34% of other toxigenic strains were resistant to clindamycin, and no resistance was found in all other cases. All the isolates were sensitive to amoxicillin/clavulanic acid in vitro. However, its use is not recommended for therapy of infections caused by C. difficile.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24114414     DOI: 10.1007/s12223-013-0283-1

Source DB:  PubMed          Journal:  Folia Microbiol (Praha)        ISSN: 0015-5632            Impact factor:   2.099


  39 in total

1.  Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.

Authors:  Jacques Pépin; Nathalie Saheb; Marie-Andrée Coulombe; Marie-Eve Alary; Marie-Pier Corriveau; Simon Authier; Michel Leblanc; Geneviève Rivard; Mathieu Bettez; Valérie Primeau; Martin Nguyen; Claude-Emilie Jacob; Luc Lanthier
Journal:  Clin Infect Dis       Date:  2005-09-20       Impact factor: 9.079

2.  MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile.

Authors:  Michelle M Butler; Dean L Shinabarger; Diane M Citron; Ciarán P Kelly; Sofya Dvoskin; George E Wright; Hanping Feng; Saul Tzipori; Terry L Bowlin
Journal:  Antimicrob Agents Chemother       Date:  2012-06-25       Impact factor: 5.191

3.  Characterization and antimicrobial susceptibility of Clostridium difficile strains isolated from adult patients with diarrhoea hospitalized in two university hospitals in Poland, 2004-2006.

Authors:  Hanna Pituch; Piotr Obuch-Woszczatyński; Dorota Wultańska; Grażyna Nurzyńska; Celine Harmanus; Aleksandra Banaszkiewicz; Andrzej Radzikowski; Mirosław Łuczak; Alex van Belkum; Ed Kuijper
Journal:  J Med Microbiol       Date:  2011-03-17       Impact factor: 2.472

4.  PCR ribotype prevalence and molecular basis of macrolide-lincosamide-streptogramin B (MLSB) and fluoroquinolone resistance in Irish clinical Clostridium difficile isolates.

Authors:  Katie Solomon; Seamus Fanning; Sinead McDermott; Sean Murray; Louise Scott; Alan Martin; Mairead Skally; Karen Burns; Ed Kuijper; Fidelma Fitzpatrick; Lynda Fenelon; Lorraine Kyne
Journal:  J Antimicrob Chemother       Date:  2011-06-27       Impact factor: 5.790

5.  Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates.

Authors:  Thomas Akerlund; Bo Svenungsson; Asa Lagergren; Lars G Burman
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

6.  Multidrug resistance in European Clostridium difficile clinical isolates.

Authors:  Patrizia Spigaglia; Fabrizio Barbanti; Paola Mastrantonio
Journal:  J Antimicrob Chemother       Date:  2011-07-19       Impact factor: 5.790

7.  Changes in antibiotic susceptibility and ribotypes in Clostridium difficile isolates from southern Scotland, 1979-2004.

Authors:  Surabhi K Taori; Val Hall; Ian R Poxton
Journal:  J Med Microbiol       Date:  2009-11-26       Impact factor: 2.472

8.  Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection.

Authors:  D M Citron; F Babakhani; E J C Goldstein; K Nagaro; S Sambol; P Sears; Y-K Shue; D N Gerding
Journal:  Anaerobe       Date:  2009-09-12       Impact factor: 3.331

9.  [Antimicrobial susceptibility of Clostridium difficile clinical isolates collected from 2001 to 2007 in a French university hospital].

Authors:  V Cattoir; Z F Ould-Hocine; P Legrand
Journal:  Pathol Biol (Paris)       Date:  2008-10-08

10.  Association between PCR ribotypes and antimicrobial susceptibility among Clostridium difficile isolates from healthcare-associated infections in South Korea.

Authors:  Jieun Kim; Jung Oak Kang; Hyunjoo Pai; Tae Yeal Choi
Journal:  Int J Antimicrob Agents       Date:  2012-05-11       Impact factor: 5.283

View more
  5 in total

1.  Self-Limited Sepsis Syndrome Following Fecal Microbiota Therapy for Refractory C. difficile Infection.

Authors:  Sundeep Singh; Emily Jing; Neil Stollman
Journal:  Dig Dis Sci       Date:  2016-09       Impact factor: 3.199

2.  Molecular typing and antimicrobial susceptibility testing to six antimicrobials of Clostridium difficile isolates from three Czech hospitals in Eastern Bohemia in 2011-2012.

Authors:  V Beran; E J Kuijper; C Harmanus; I M Sanders; S M van Dorp; C W Knetsch; J Janeckova; A Seidelova; L Barekova; J Tvrdik; D Chmelar; I Ciznar
Journal:  Folia Microbiol (Praha)       Date:  2017-03-22       Impact factor: 2.099

3.  C. difficile ribotype 027 or 176?

Authors:  Marcela Krutova; Jana Matejkova; Otakar Nyc
Journal:  Folia Microbiol (Praha)       Date:  2014-06-27       Impact factor: 2.099

4.  Making life difficult for Clostridium difficile: augmenting the pathogen's metabolic model with transcriptomic and codon usage data for better therapeutic target characterization.

Authors:  Sara Saheb Kashaf; Claudio Angione; Pietro Lió
Journal:  BMC Syst Biol       Date:  2017-02-16

5.  Genotyping and Antimicrobial Susceptibility of Clostridium perfringens and Clostridioides difficile in Camel Minced Meat.

Authors:  Mahmoud Fayez; Waleed R El-Ghareeb; Ahmed Elmoslemany; Saleem J Alsunaini; Mohamed Alkafafy; Othman M Alzahrani; Samy F Mahmoud; Ibrahim Elsohaby
Journal:  Pathogens       Date:  2021-12-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.